Anavex Life Sciences Corp (AVXL)

[powerwalker]

The Lilly drug is called solanezumab. I believe it has failed two other trials.

I was scheduled to be include in a P3 study of solanezumab at Rush Hospital in Chicago late last year until I read the following risks, at which time I bowed out:

RISKS: There are known and unknown risks with this study. You might
experience all, some, or none of the side effects listed. The main risks involve
the study drug. The drug has been used in humans before. Serious symptoms
that have occurred more often in people receiving solanezumab include chest
pain, heart failure, and fainting.
[ORA: 13111101-IRB01-CR01 Date IRB Approved: 3/11/2015 Expiration Date: 3/11/2016
Template Version Date: 02/07/2012 A4 US ICF v3.0 23-SEP-2014
Consent Version Date: 12/08/2014 2 of 18].
There were 43 deaths that occurred during completed long-term studies of
solanezumab. Of these, 24 subjects had received solanezumab and 19 subjects
had received placebo.
Other risks involve study activities such as blood collection, electrical heart
activity tests, brain scans, and spinal fluid tests. Study risks are further
explained in the detailed section below. We take your privacy seriously. To
protect your privacy, we will label your data and samples with a special code.
We will store your name and contact information in a separate, secure place.